References
- Rijken D C, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815–30
- Holmberg L, Kristoffersson A C, Lecander I, Wallén P, Åstedt B. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase. Scand J Clin Lab Invest 1982; 42: 347–54
- Levin E G. Latent tissue plasminogen activator produced by human endothelial cells in culture: Evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804–8
- Åstedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 1976; 261: 595–7
- Danø K, Andreasen P A, Grøndahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139–266
- Rijken D C, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035–41
- Wennerberg J. Changes in growth pattern in human squamous cell carcinoma of the head and neck during serial passages in nude mice. Int J Cancer 1984; 33: 245–50
- Pandolfi M, Bjernstad A, Nilsson I M. Technical remarks on microscopical demonstration of tissue plasminogen activator. Thromb Diathes Haemorrh 1972; 27: 88–98
- Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346–51
- Åstedt B, Holmberg L, Lecander I, Thorell J. Radio-immunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures. Eur J Cancer 1981; 17: 239–44
- Ljungnér H, Holmberg L, Kjaeldgaard A, Nilsson I M, Åstedt B. Immunological characterization of plasminogen activators in a human vessel wall. J Clin Pathol 1983; 36: 1046–9
- Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223–34
- Husain S S, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31–8
- Holmberg L, Bladh B, Åstedt B. Purification of urokinase by affinity chromatography. Biochim Biophys Acta 1976; 445: 215–22
- Åstedt B, Pandolfi M. Ontogenesis of tissue plasminogen activator in the human. Thromb Diathes Haemorrh 1971; 25: 469–80
- Åstedt B, Barlow G, Holmberg L. Time-related release of various molecular forms of urokinase in tissue culture. Thromb Res 1977; 11: 149–53
- Åstedt B, Lundgren E, Roos G, Abu Sinna G. Release of various molecular forms of plasminogen activators during culture of human ovarian tumours. Thromb Res 1978; 13: 1031–7
- Peterson H I. Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumours. Cancer Treat Rev 1977; 4: 213–7
- Åstedt B. Adjuvant treatment of ovarian carcinoma with tranexamic acid. J Clin Pathol 33: Suppl, Roy Coll Path 1980; 14: 74–6
- Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611–9